Vitamin
Vitamin D + Fish Oil for Health Improvement
This trial is studying whether taking daily dietary supplements of vitamin D3 or omega-3 fatty acids reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses.
Monoclonal Antibodies
Rituximab + Cyclosporine for Glomerulonephritis
This trial is testing the safety and effectiveness of combining two drugs to treat membranous nephropathy, a kidney disease associated with damage to the walls of the glomeruli. The first drug, rituximab, is an immunosuppressant that attempts to reduce the activity of the immune system. The second drug, cyclosporine, is a blood pressure lowering medication. The trial will last up to 2 years, and participants will have frequent blood and urine tests.
Alkylating agents
Stem Cell Transplant for Autoimmune Neurological Diseases
This trial tests a combination of strong chemotherapy and an immune-suppressing medicine followed by a stem cell transplant. It targets patients with autoimmune neurological diseases that haven't improved with other treatments. The treatment aims to weaken the immune system to stop it from attacking the nervous system and then helps the body recover by making new blood cells. High-dose chemotherapy followed by a stem cell transplant has been shown to improve various autoimmune diseases.
Anti-metabolites
ADI-001 for Lupus Nephritis
This trial is testing a new treatment for lupus nephritis in multiple centers. It will involve different stages like screening, treatment, and follow-up to find the appropriate dose and assess its safety and effectiveness
Popular Filters
Trials for Multiple Sclerosis Patients
Behavioral Intervention
Parent Group Education for Adolescent Type 1 Diabetes Transition
This trial will test if group education for parents of teens with type 1 diabetes helps improve the transition to adulthood. The study focuses on parents and aims to teach them how to better support their children in managing their diabetes. The goal is to see if these sessions can make a positive difference in the teens' health and self-management.
Stem Cell Therapy
Stem Cell Therapy for Chronic and Acute Conditions
This trial is testing stem cell therapy, which uses special cells to repair or replace damaged tissues. It targets patients with a range of acute and chronic conditions that may not respond well to traditional treatments. The therapy works by transforming stem cells into the needed cell types to improve organ and tissue function.
Anti-bacterial
Oral Antibiotics for Prosthetic Joint Infections
This trial is testing whether a 7-day course of an oral, prophylactic antibiotic can reduce the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
Neurostimulation Device
VNS for Epilepsy
This trial is studying whether vagal nerve stimulation (VNS) for epilepsy affects bowel habits and the gut microbiome. VNS is a neurosurgical procedure where an impulse generator is placed near the vagus nerve in the neck.
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Trials for Autoimmune Diseases Patients
Behavioral Intervention
Parent Group Education for Adolescent Type 1 Diabetes Transition
This trial will test if group education for parents of teens with type 1 diabetes helps improve the transition to adulthood. The study focuses on parents and aims to teach them how to better support their children in managing their diabetes. The goal is to see if these sessions can make a positive difference in the teens' health and self-management.
Stem Cell Therapy
Stem Cell Therapy for Chronic and Acute Conditions
This trial is testing stem cell therapy, which uses special cells to repair or replace damaged tissues. It targets patients with a range of acute and chronic conditions that may not respond well to traditional treatments. The therapy works by transforming stem cells into the needed cell types to improve organ and tissue function.
Anti-bacterial
Oral Antibiotics for Prosthetic Joint Infections
This trial is testing whether a 7-day course of an oral, prophylactic antibiotic can reduce the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
Neurostimulation Device
VNS for Epilepsy
This trial is studying whether vagal nerve stimulation (VNS) for epilepsy affects bowel habits and the gut microbiome. VNS is a neurosurgical procedure where an impulse generator is placed near the vagus nerve in the neck.
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Trials With No Placebo
Behavioral Intervention
Parent Group Education for Adolescent Type 1 Diabetes Transition
This trial will test if group education for parents of teens with type 1 diabetes helps improve the transition to adulthood. The study focuses on parents and aims to teach them how to better support their children in managing their diabetes. The goal is to see if these sessions can make a positive difference in the teens' health and self-management.
Stem Cell Therapy
Stem Cell Therapy for Chronic and Acute Conditions
This trial is testing stem cell therapy, which uses special cells to repair or replace damaged tissues. It targets patients with a range of acute and chronic conditions that may not respond well to traditional treatments. The therapy works by transforming stem cells into the needed cell types to improve organ and tissue function.
Anti-bacterial
Oral Antibiotics for Prosthetic Joint Infections
This trial is testing whether a 7-day course of an oral, prophylactic antibiotic can reduce the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
Neurostimulation Device
VNS for Epilepsy
This trial is studying whether vagal nerve stimulation (VNS) for epilepsy affects bowel habits and the gut microbiome. VNS is a neurosurgical procedure where an impulse generator is placed near the vagus nerve in the neck.
Stem Cell Transplant
Bone Marrow/Kidney Transplant for Blood Disorders & Chronic Kidney Disease
This trial is for a combined bone marrow and kidney transplant from a partially matched related donor to treat a blood disorder and kidney disease. The expectation is to have 10 people participate.
Frequently Asked Questions
Introduction to autoimmune disease
What are the top hospitals conducting autoimmune disease research?
When it comes to cutting-edge clinical trials in the field of autoimmune diseases, several top hospitals are making significant strides. Massachusetts General Hospital in Boston leads the pack with three active trials and a total of seven completed trials focused on these complex conditions. This renowned institution has been at the forefront of autoimmune disease research since recording its first trial in 2005.
Meanwhile, Mayo Clinic located in Rochester, Minnesota is another respected center for medical innovation. With two ongoing autoimmune disease trials and a total of four completed studies, Mayo Clinic entered this arena in 2010 and has been actively contributing ever since.
The National Institutes of Health (NIH) Clinical Center located in Bethesda, Maryland also plays a vital role in advancing our understanding and treatment options for autoimmune diseases. Currently conducting two active clinical trials for these conditions, NIH has recorded five previous studies since initiating their first trial back in 2009.
In New york City's prestigious Hospital for Special Surgery, researchers are focusing on exploring novel interventions for individuals suffering from autoimmune diseases. With two ongoing clinical trials and a record of three previously conducted studies from their inaugural exploration launched just four years ago in 2017; they have quickly made their mark within this specialized field.
Lastly but by no means least University of Alberta situated within Edmonton takes pride as it pioneers new paths towards treating autoimmune disorders with one currently running trial while already managing to hold credit completing not only trialing experiments but being able commenced those endeavors as well starting merely early this year during2022 .
These esteemed institutions highlight the dedication and commitment to finding effective treatments for individuals affected by various forms of autoimmunity across North America. Through rigorous research efforts like these clinical trials, scientists strive to uncover breakthroughs that will ultimately lead us closer to improved management strategies or even cures for these often life-altering conditions
Which are the best cities for autoimmune disease clinical trials?
Boston, Massachusetts; New york, New York; Saint Louis, Missouri; Bethesda, Maryland; and Philadelphia, Pennsylvania are among the top cities for autoimmune disease clinical trials. These cities have a significant number of active studies aimed at advancing treatments for various autoimmune conditions. With varying numbers of ongoing trials and diverse investigational approaches such as Nivolumab, Rituximab Infusion, and Oral Ifetroban, these cities offer individuals with autoimmune diseases access to cutting-edge research opportunities that may ultimately lead to improved management options and better quality of life.
Which are the top treatments for autoimmune disease being explored in clinical trials?
The world of autoimmune disease research is constantly evolving, and there are a few standout treatments that have shown promise in recent clinical trials. Peresolimab has emerged as a frontrunner, currently being studied in one active trial for autoimmune disease. Although it's relatively new to the scene with only one all-time trial since its listing in 2022, peresolimab holds great potential for patients seeking effective treatment options. Another contender making waves is Diamyd, which also boasts one active trial and has been involved in two all-time trials since its introduction in 2017. As researchers delve deeper into these innovative therapies, hope continues to grow for those living with autoimmune diseases worldwide.
What are the most recent clinical trials for autoimmune disease?
Promising advancements in the field of autoimmune disease have emerged through recent clinical trials. One notable study explores the potential benefits of depleting CD3/CD19 during autologous stem cell transplants. This Phase 2 trial, available since September 1, 2023, aims to uncover new approaches for treating autoimmune diseases. Another trial investigates KYV-101 CAR-T cells with lymphodepletion conditioning in Phase 1. By utilizing this innovative method along with comprehensive monitoring and evaluation, researchers hope to develop effective therapies against autoimmune diseases. Additionally, VCTX211 unit is undergoing combined Phase 1 and Phase 2 trials as of January 20, 2023—a significant step towards enhancing treatment options for those affected by these challenging conditions. With these groundbreaking studies paving the way forward, patients living with autoimmune diseases can look toward a future marked by improved outcomes and quality of life.
What autoimmune disease clinical trials were recently completed?
Recent clinical trials have made significant strides in the field of autoimmune disease research. Notably, a trial sponsored by CRISPR Therapeutics AG concluded in January 2022, exploring the potential of VCTX210A unit as a treatment option. Additionally, Suzhou Connect Biopharmaceuticals' CBP-307 underwent successful testing and completed its trial in June 2021. It is worth mentioning that Bristol-Myers Squibb's branebrutinib study reached completion back in January 2020. These developments highlight ongoing efforts to advance our understanding and treatment options for autoimmune diseases, providing hope for patients worldwide facing these conditions.